D. Chapman

发表

3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.

N. Cosford, Merryl D. Cramer, Nicholas D Smith, 2004, Bioorganic & medicinal chemistry letters.

2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.

Dehua Huang, N. Cosford, Merryl D. Cramer, 2004, Bioorganic & medicinal chemistry letters.

[3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine Binding to Metabotropic Glutamate Receptor Subtype 5 in Rodent Brain: In Vitro and in Vivo Characterization

Nicholas D. P. Cosford, N. Cosford, M. Bradbury, 2002, Journal of Pharmacology and Experimental Therapeutics.

3‐[3‐Fluoro‐5‐(5‐pyridin‐2‐yl‐2H‐tetrazol‐2‐yl)phenyl] ‐4‐methylpyridine: A Highly Potent and Orally Bioavailable Metabotropic Glutamate Subtype 5 (mGlu5) Receptor Antagonist.

N. Cosford, Merryl D. Cramer, G. Holtz, 2005 .

Comparison of TNK With Wild-Type Tissue Plasminogen Activator in a Rabbit Embolic Stroke Model

P. Lyden, P. Lapchak, J. Zivin, 2001, Stroke.

Pharmacological Effects of the Spin Trap Agents N-t-Butyl-Phenylnitrone (PBN) and 2,2,6,6-Tetramethylpiperidine-N-Oxyl (TEMPO) in a Rabbit Thromboembolic Stroke Model: Combination Studies With the Thrombolytic Tissue Plasminogen Activator

P. Lapchak, J. Zivin, D. Chapman, 2001, Stroke.

3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.

N. Cosford, Merryl D. Cramer, J. Roppe, 2005, Bioorganic & medicinal chemistry letters.

Dehydroepiandrosterone sulfate is neuroprotective in a reversible spinal cord ischemia model: possible involvement of GABA(A) receptors.

P. Lapchak, J. Zivin, D. Chapman, 2000, Stroke.

Metabotropic glutamate receptor 5 antagonist-induced stimulation of hypothalamic–pituitary–adrenal axis activity: interaction with serotonergic systems

M. Bradbury, H. Schaffhauser, G. Holtz, 2003, Neuropharmacology.

In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine).

N. Cosford, M. Bradbury, Jeffery J. Anderson, 2003, European journal of pharmacology.

Metabotropic Glutamate Receptor mGlu5 Is a Mediator of Appetite and Energy Balance in Rats and Mice

N. Cosford, M. Bradbury, U. Campbell, 2005, Journal of Pharmacology and Experimental Therapeutics.

Metabotropic Glutamate Receptor mGlu 5 Is a Mediator of Appetite and Energy Balance in Rats and Mice

N. Cosford, M. Bradbury, U. Campbell, 2004 .

Dehydroepiandrosterone Sulfate Is Neuroprotective in a Reversible Spinal Cord Ischemia Model : Possible Involvement of GABAA Receptors Editorial Comment: Possible Involvement of GABAA Receptors

C. Hsu, P. Lapchak, J. Zivin, 2000 .

2‐{2‐[3‐(Pyridin‐3‐yloxy)phenyl]‐2H‐tetrazol‐5‐yl}pyridine: A Highly Potent, Orally Active, Metabotropic Glutamate Subtype 5 (mGlu5) Receptor Antagonist.

N. Cosford, Merryl D. Cramer, J. Roppe, 2005 .